Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The co-primary objectives will be to assess the safety and quality of life under treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut Paoli-Calmettes
• Collaborator: Société Francophone d'Onco-Gériatrie
• Treatments: Immune Checkpoint Inhibitors; Immunologic Factors

Criteria

Inclusion Criteria:

• Patients eligible to start a treatment including immune checkpoint inhibitors (Nivolumab, Ipilimumab, Pembrolizumab, and so on…)

• Diagnosis of advanced or metastatic melanoma or NSCLC (All treatment lines will be allowed)

• Age ≥ 70 years

• Having personally signed and dated informed consent

• Patient affiliated to the ''National security'' regimen or beneficiary of this regimen

Exclusion Criteria:

• Immune checkpoint inhibitor therapy initiated before study enrolment

• Concomitant participation in other investigational clinical trials involving an immune checkpoint inhibitor

• Immune checkpoint inhibitor treatment in a context of other solid tumours

• Immune checkpoint inhibitor treatment in a context of haematological malignancies

• Being unable or unwilling to comply with the requirements of the protocol, as assessed by the investigator

• Patient in urgency situation, adult under legal protection, or unable to give his consent